<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675151</url>
  </required_header>
  <id_info>
    <org_study_id>OPI-NYXP-201 (VEGA-1)</org_study_id>
    <nct_id>NCT04675151</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia</brief_title>
  <official_title>Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) With Pilocarpine Eye Drops in Subjects With Presbyopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocuphire Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocuphire Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are:&#xD;
&#xD;
      To evaluate the efficacy of Nyxol + Pilocarpine to improve DCNVA in subjects with presbyopia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Actual">May 17, 2021</completion_date>
  <primary_completion_date type="Actual">May 17, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects with ≥ 15 letters of improvement in photopic binocular DCNVA</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>The percent of subjects with ≥ 15 letters of improvement in photopic binocular DCNVA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with improvement of ≥ 5, ≥ 10, and ≥ 15 letters in DCNVA (photopic) from Baseline</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>The percentage of subjects with improvement of ≥ 5, ≥ 10, and ≥ 15 letters in DCNVA (photopic) from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with improvement of ≥ 15 letters in DCNVA (photopic) at 1 hour and with &lt; 5 letters of loss in photopic binocular BCDVA from Baseline</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>The percentage of subjects with improvement of ≥ 15 letters in DCNVA (photopic) at 1 hour and with &lt; 5 letters of loss in photopic binocular BCDVA from Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with improvement in BCIVA (photopic) from Baseline</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>The percentage of subjects with improvement in BCIVA (photopic) from Baseline of ≥ 5, ≥ 10, and ≥ 15 letters</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Nyxol + Pilocarpine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 drop of Nyxol (Treatment 1) and 1 drop of Pilocarpine (Treatment 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nyxol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop of Nyxol (Treatment 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pilocarpine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 drop of Pilocarpine (Treatment 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 drop of Placebo (Treatment 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentolamine Ophthalmic Solution 0.75%</intervention_name>
    <description>0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist</description>
    <arm_group_label>Nyxol</arm_group_label>
    <arm_group_label>Nyxol + Pilocarpine</arm_group_label>
    <other_name>Nyxol</other_name>
    <other_name>Nyxol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pilocarpine</intervention_name>
    <description>Pilocarpine ophthalmic solution</description>
    <arm_group_label>Nyxol + Pilocarpine</arm_group_label>
    <arm_group_label>Pilocarpine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Topical sterile ophthalmic solution</description>
    <arm_group_label>Pilocarpine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Phentolamine Ophthalmic Solution Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females ≥ 40 and ≤ 64years of age.&#xD;
&#xD;
          2. BCDVA of 0.0 LogMAR(20/20 Snellen equivalent) or better in each eye under photopic&#xD;
             conditions.&#xD;
&#xD;
          3. DCNVA of 0.4 LogMAR (20/50 Snellen equivalent) or worse under photopic conditions in&#xD;
             each eye and binocularly.&#xD;
&#xD;
          4. Subjects who depend on reading glasses or bifocals in which their binocular&#xD;
             best-corrected near VA is 0.1 LogMAR (20/25 Snellen equivalent) or better.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ophthalmic (in either eye):&#xD;
&#xD;
          1. Use of any topical prescription or OTC ophthalmic medications of any kind within 7&#xD;
             days of Screening until study completion.&#xD;
&#xD;
          2. Use of any over-the-counter (OTC) artificial tears (preserved or unpreserved) at least&#xD;
             once per day within 7 days of Screening until study completion.&#xD;
&#xD;
          3. Current use of any topical ophthalmic therapy for dry eye.&#xD;
&#xD;
          4. Tear break-up time of &lt; 5 seconds or corneal fluorescein staining.&#xD;
&#xD;
          5. Clinically significant ocular disease that might interfere with the study as deemed by&#xD;
             the Investigator.&#xD;
&#xD;
          6. Recent or current evidence of ocular infection or inflammation in either eye.&#xD;
&#xD;
          7. Any history of herpes simplex or herpes zoster keratitis.&#xD;
&#xD;
          8. History of diabetic retinopathy or diabetic macular edema.&#xD;
&#xD;
          9. Known allergy, hypersensitivity, or contraindication to any component of the&#xD;
             phentolamine, pilocarpine, or vehicle formulations.&#xD;
&#xD;
         10. History of cauterization of the punctum or punctal plug (silicone or collagen)&#xD;
             insertion or removal.&#xD;
&#xD;
         11. Ocular trauma, ocular surgery, ocular laser treatment within the 6 months prior to&#xD;
             Screening. Any subject with multifocal intraocular lenses are excluded.&#xD;
&#xD;
         12. History of any traumatic (surgical or nonsurgical) or non traumatic condition&#xD;
             affecting the pupil or iris.&#xD;
&#xD;
         13. Unwilling or unable to discontinue use of contact lenses.&#xD;
&#xD;
         14. Conjunctival hyperemia ≥ grade 2 on the CCLRU 4-point scale.&#xD;
&#xD;
             Systemic:&#xD;
&#xD;
         15. Known hypersensitivity or contraindication to alpha- and/or beta adrenoceptor&#xD;
             antagonists.&#xD;
&#xD;
         16. Known hypersensitivity or contraindication to any systemic cholinergic&#xD;
             parasympathomimetic agents.&#xD;
&#xD;
         17. Clinically significant systemic disease that might interfere with the study as deemed&#xD;
             by the Investigator.&#xD;
&#xD;
         18. Participation in any investigational study within 30 days prior to Screening.&#xD;
&#xD;
         19. Females of childbearing potential who are pregnant, nursing, planning a pregnancy, or&#xD;
             not using a medically acceptable form of birth control.&#xD;
&#xD;
         20. Resting HR outside the specified range of 50 to 110 beats per minute.&#xD;
&#xD;
         21. Hypertension with resting diastolic BP &gt; 105 mmHg or systolic BP &gt; 160 mmHg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Site 12</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 6</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 13</name>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <zip>34461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 5</name>
      <address>
        <city>Longwood</city>
        <state>Florida</state>
        <zip>32779</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 11</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 8</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 10</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 3</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 18</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 16</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 14</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 2</name>
      <address>
        <city>Athens</city>
        <state>Ohio</state>
        <zip>45701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 9</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 7</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 15</name>
      <address>
        <city>Powell</city>
        <state>Ohio</state>
        <zip>43065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 4</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02888</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site 1</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nyxol</keyword>
  <keyword>Presbyopia</keyword>
  <keyword>Pilocarpine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phentolamine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pilocarpine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

